IVD Assay Development
Seraseq® FFPE NTRK Fusion RNA Reference Material
Details
Resources
Specifications
Frequently Asked Questions
Neurotrophic tyrosine receptor kinases (NTRK) can become abnormally fused to other genes resulting in growth signals that can lead to cancer in many organs of the human body. Anti-tumor drugs that target NTRK fusions have been shown to be largely effective across many tumor types regardless of patient age (adult or pediatric), especially in locally advanced or metastatic solid tumors. This product expands SeraCare's RNA Fusion FFPE reference material product portfolio to support routine clinical diagnostic / companion diagnostic (CDx) use for solid tumor testing of tissue biopsies for NTRK fusion genes in cancer disease diagnosis and treatment selection.
- 15 clinically-relevant NTRK fusion genes in a single reference sample
- Offered as FFPE for full process assay (NGS or PCR) workflow monitoring and patient testing
- Fusions precisely quantitated with digital PCR
- Well-characterized GM24385 human genomic RNA as background wild-type material
- Manufactured in GMP-compliant and ISO 13485-certified facilities
Seraseq FFPE NTRK Fusion RNA Reference Material
Seraseq FFPE NTRK Fusion RNA Reference Material
Seraseq FFPE NTRK Fusion RNA Reference Material
Seraseq FFPE NTRK Fusion RNA Reference Material
Seraseq FFPE NTRK Fusion RNA Reference Material
Seraseq FFPE NTRK Fusion RNA Reference Material
Seraseq FFPE NTRK Fusion RNA Reference Material
Technical Spreadsheet for Seraseq® FFPE NTRK Fusion RNA Reference Material
Seraseq NTRK Fusion RNA Reference Materials
Seraseq FFPE Safety Data Sheet
| Varaiant List | |||
| Fusion RNA | 5' Partner | 3' Partner | HGVS Name |
| TPM3-NTRK1 | TPM3 exon 7 | NTRK1 exon 9 | TPM3{ENST00000368533}:r.1_717_NTRK1{ENST00000392302}:r.1262_2609 |
| LMNA-NTRK1 | LMNA exon 11 | NTRK1 exon 11 | LMNA {ENST00000368299}:r.1:2015_NTRK1{ENST00000392302}:r.1318_2609 |
| IRF2BP2-NTRK1 | IRF2BP2 exon 1 | NTRK1 exon 9 | IRF2BP2{ENST00000366609}:r.1_1079_NTRK1{ENST00000392302}:r.1262_2609 |
| SQSTM1-NTRK1 | SQSTM1 exon 5 | NTRK1 exon 9 | SQSTM1{ENST00000389805}:r.1_932_NTRK1{ENST00000392302}:r.1262_2609 |
| TFG-NTRK1 | TFG exon 5 |
NTRK1 exon 9 | TFG{ENST00000240851}:r.1_920_NTRK1{ENST00000392302}:r.1262_2609 |
| AFAP1-NTRK2 | AFAP1 exon 14 | NTRK2 exon 10* | AFAP1{ENST00000420658.1}:r.1_2170_NTRK2{ENST00000376214}:r.2098_5608 |
| NACC2-NTRK2 | NACC2 exon 4 | NTRK2 exon 11* | NACC2{ENST00000371753}:r.1_1314_NTRK2{ENST00000376214}:r.2134_5608 |
| QKI-NTRK2 | QKI exon 6 |
NTRK2 exon 14* | QKI{ENST00000361752}:r.1_1485_NTRK2{ENST00000376214}:r.2383_5608 |
| TRIM24-NTRK2 | TRIM24 exon 12 | NTRK2 exon 13* | TRIM24{ENST00000343526}:r.1_2229_NTRK2{ENST00000376214}:r.2335_5608 |
| PAN3-NTRK2 | PAN3 exon 1 | NTRK2 exon 15* | PAN3{ENST00000380958}:r.1_582_NTRK2{ENST00000376214}:r.2572_5608 |
| ETV6-NTRK3 | ETV6 exon 5 | NTRK3 exon 14 | ETV6{ENST00000396373}:r.1_1283_NTRK3{ENST00000394480}:r.1719_19984 |
| ETV6-NTRK3 | ETV6 exon 5 | NTRK3 exon 15 | ETV6{ENST00000396373}:r.1_1283_NTRK3{ENST00000394480}:r.1908_19984 |
| ETV6-NTRK3 | ETV6 exon 4 | NTRK3 exon 15 | ETV6{ENST00000396373}:r.1_737_NTRK3{ENST00000394480}:r.1908_19984 |
| ETV6-NTRK3 | ETV6 exon 4 | NTRK3 exon 14 | ETV6{ENST00000396373}:r.1_737_NTRK3{ENST00000394480}:r.1719_19984 |
| BTBD1-NTRK3 | BTBD1 exon 4 | NTRK3 exon 14 | BTBD1{ENST00000261721}:r.1_1065_NTRK3{ENST00000394480}:r.1719_19984 |
*NTRK2 has multiple splice isoforms which makes exon numbering challenging. These numbers correspond to Transcript: NTRK2-201 ENST00000277120.7.
For research use only. Not for use in diagnostic procedures.
Solid Tumor FAQs
Review the common questions we receive from our customers and the responses we provide.